Inclusion Criteria:

          -  Postmenopausal women with metastatic, recurrent or locally advanced breast cancer not
             amenable to curative treatment by surgery or radiotherapy.

          -  Histological or cytological confirmation of hormone-receptor positive (HR+) breast
             cancer.

          -  Disease refractory to non-steroidal aromatase inhibitors, defined as:

          -  Recurrence while on, or within 12 months (365 days) of completion of adjuvant therapy
             with letrozole or anastrozole, or

          -  Progression while on, or within one month (30 days) of completion of letrozole or
             anastrozole treatment for locally advanced or metastatic breast cancer (ABC).

          -  Radiological or objective evidence of recurrence or progression on or after the last
             systemic therapy prior to enrolment.

          -  Patients must have had:

          -  At least one lesion that could have been accurately measured in at least one dimension

               -  20 mm with conventional imaging techniques or ≥ 10 mm with spiral CT or MRI, or

          -  Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as
             defined above.

          -  Adequate bone marrow, coagulation, liver and renal function.

          -  ECOG performance status ≤ 2.

        Exclusion Criteria:

          -  Patients overexpressing HER2 by local laboratory testing (IHC 3+ staining or in situ
             hybridization positive). Patients with IHC 2+ must have a negative in situ
             hybridization test.

          -  Patients with only non-measurable lesions other than bone metastasis (e.g. pleural
             effusion, ascites).

          -  Patients with more than one prior chemotherapy line for ABC. A chemotherapy line is an
             anticancer regimen(s) that contained at least 1 cytotoxic chemotherapy agent, given
             for a minimum of 21 days.

          -  Previous treatment with mTOR inhibitors.

          -  Known hypersensitivity to mTOR inhibitors, e.g. Sirolimus (rapamycin).

          -  Patients with a known history of HIV seropositivity. Screening for HIV infection at
             baseline was not required.

          -  Patient who were being treated with drugs recognized as being strong inhibitors or
             inducers of the isoenzyme CYP3A

          -  History of brain or other CNS metastases, including leptomeningeal metastasis.